Home > Overview

Founded in 2001, TaiGen Biotechnology Co., Ltd. (“TaiGen Taiwan” or “TaiGen”) is a research-based and product-driven pharmaceutical company engaging in the development of novel therapeutics for infectious diseases. TaiGen has a wholly-owned Beijing subsidiary with a proven capacity to conduct clinical trials and related registrations. There are 70 FTEs in Taipei and Beijing offices with 80% staffs engaging in R&D activities.

TaiGen was listed in Taiwan OTC Stock Market on the 17th Jan. 2014. To date, there are approx. 716 million shares issued and outstanding, each with par value of US$0.001. TaiGen’s principle shareholders include Yuen Foong Yu (YFY) Group, Taiwan’s National Development Fund, Taiwan Sugar Corporation, Yao-Hwa Glass Management Commission, and Taiwan Global BioFund.

TaiGen is a fully-integrated pharmaceutical company combining drug discovery & development, global regulatory approval & registration, and commercialization in China. This business strategy capitalizes on the extensive expertise by senior executives whom were recruited from major pharma in the West and from Asian-based multinational companies. The pipeline includes internal discovery as well as in-licensing molecules that with global focus and emphasis on Asian-prevalent diseases.

An operation platform that support product development, sales and marketing in the Greater China has been established by TaiGen, and the business activities also expand to the alliance with key players worldwide. With the new business model, TaiGen successfully out-licensed Taigexyn® to more than 30 countries and continue expanding its territory.

TaiGen's goal is to develop "first-in-class" and "best-in-class" products with worldwide IP rights.